Company Profile
Discure Technologies Ltd. is an Israel-based clinical-stage manufacturer of implantable bioelectronic devices for orthopedic regeneration, headquartered in Petach-Tikva, Israel. Founded in 2019 by Rainbow Medical Innovations, the company operates as an independent privately held entity, led by Chief Executive Officer Yuval Mandelbaum. Discure Technologies is pioneering disease-modifying therapy for degenerative disc disease (DDD), with First-in-Human clinical trials underway in Canada and Italy.
Core Products ＆ Technologies
The Discure System
• Implantable Pulse Generator (IPG): Subcutaneously placed bioelectronic generator with 17-year battery life
• Intradiscal Lead: Thin electrode delivered via needle injection into the intervertebral disc nucleus
• Physician Programmer: Remote system for programming treatment parameters and monitoring therapy delivery
• Mechanism of Action: Actively controls electroosmotic inflow of fluids, oxygen, and nutrients to regenerate disc tissue
Clinical Development ＆ Pipeline
• First-in-Human Trials: Ongoing clinical studies in Canada and Italy demonstrating favorable safety and efficacy
• Platform Technology: Potential expansion to hip, shoulder, and knee orthopedic indications beyond DDD
• Combination Therapies: Compatible with gene and cell therapies to enhance chondrocyte regeneration
Market Position ＆ Certifications
Discure Technologies holds a pioneering position in the disease-modifying DDD market, competing with Mainstay Medical (ReActiv8) and symptom-management alternatives. Key strengths include:
• 6+ years of bioelectronic implant development heritage
• FDA Breakthrough Device Designation: Granted in 2021 for the Discure System
• FDA TAP Program: Accepted into the Total Product Life Cycle Advisory Program in 2025
• Patent portfolio: 7 filed patents including granted electroosmotic tissue treatment IP (2025)
• Clinical validation: Positive preliminary results from First-in-Human trials in multiple countries
Corporate Timeline
2019 — Founded in Petach-Tikva by Rainbow Medical Innovations to develop bioelectronic disc regeneration therapy
2021 — Received FDA Breakthrough Device Designation for the Discure System
2024 — Secured $16 million total financing ($11M Series A led by BOLD Capital Partners, Supernova Invest, and Sanara Capital)
2025 — Granted U.S. patent for electroosmotic tissue treatment; accepted into FDA TAP Program
2026 — Preparing to initiate pivotal study to support De Novo approval pathway; continues First-in-Human clinical trials
Target Markets ＆ Applications
• Chronic Low Back Pain: Disease-modifying implant for mid-stage DDD to reduce opioid dependence and avoid invasive surgery
• Interventional Spine: Outpatient, minimally invasive procedure for pain management and orthopedic specialists
• Orthopedic Regeneration: Platform bioelectronic technology expandable to hip, shoulder, and knee applications
• Combination Biologics: Adjunct therapy to enhance microenvironment for gene and cell-based disc repair
Contact Information
Global Headquarters
Address: 61 Jabotinsky St., BSR Towers, Petach-Tikva, Israel
Email: info@discuremd.com
Website: www.discuremd.com
Investor ＆ Media Relations
Discure Technologies Ltd.
Status: Privately held (Series A)
Key Investors: BOLD Capital Partners, Supernova Invest, Sanara Capital, JJDC, UVM Health Network Ventures
LinkedIn: linkedin.com/company/discure-technologies
